OxVax focused on the development of an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumor cancers.
OXvax Ltd. is a spin-out company from the University of Oxford focused on the development of an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumor cancers.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 21, 2021 | Seed | — | 2 | Evotec Lead Compass Investment | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Evotec | Yes | Seed |
Lead Compass Investment | Yes | Seed |